Nothing Special   »   [go: up one dir, main page]

CY1107819T1 - Φαρμακευτικη διαμορφωση της ολανζαπινης - Google Patents

Φαρμακευτικη διαμορφωση της ολανζαπινης

Info

Publication number
CY1107819T1
CY1107819T1 CY20071101537T CY071101537T CY1107819T1 CY 1107819 T1 CY1107819 T1 CY 1107819T1 CY 20071101537 T CY20071101537 T CY 20071101537T CY 071101537 T CY071101537 T CY 071101537T CY 1107819 T1 CY1107819 T1 CY 1107819T1
Authority
CY
Cyprus
Prior art keywords
olanzapin
pharmaceutical form
olanzapine
monosaccharide
oligosaccharide
Prior art date
Application number
CY20071101537T
Other languages
English (en)
Inventor
Stanka Perc
Ivanka Banko
Ivanka Kolenc
Original Assignee
Krka, Tovarna Zdravil, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32173824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107819(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka, Tovarna Zdravil, D.D., Novo Mesto filed Critical Krka, Tovarna Zdravil, D.D., Novo Mesto
Publication of CY1107819T1 publication Critical patent/CY1107819T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Φαρμακευτική διαμόρφωση η οποία περιέχει ένα ομογενές μίγμα (α) ολανζαπίνης ή ενός φαρμακολογικώς αποδεκτού άλατος της ως δραστικού συστατικού, (β) ενός μονοσακχαρίτη ή/και ολιγοσακχαρίτη, (γ) ενός πολυσακχαρίτη και, προαιρετικώς, περαιτέρω συστατικών.
CY20071101537T 2002-10-18 2007-12-03 Φαρμακευτικη διαμορφωση της ολανζαπινης CY1107819T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200200255A SI21303A (sl) 2002-10-18 2002-10-18 Farmacevtska formulacija olanzapina
EP03751723A EP1558219B1 (en) 2002-10-18 2003-10-16 Pharmaceutical formulation of olanzapine

Publications (1)

Publication Number Publication Date
CY1107819T1 true CY1107819T1 (el) 2013-06-19

Family

ID=32173824

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101537T CY1107819T1 (el) 2002-10-18 2007-12-03 Φαρμακευτικη διαμορφωση της ολανζαπινης

Country Status (18)

Country Link
US (2) US20050288276A1 (el)
EP (1) EP1558219B1 (el)
AT (1) ATE374600T1 (el)
AU (1) AU2003269792A1 (el)
CA (1) CA2502582C (el)
CY (1) CY1107819T1 (el)
DE (1) DE60316714T2 (el)
DK (1) DK1558219T3 (el)
EA (1) EA008516B1 (el)
ES (1) ES2295626T3 (el)
HR (1) HRP20050342B1 (el)
NO (1) NO20052408L (el)
PL (1) PL206217B1 (el)
PT (1) PT1558219E (el)
RS (1) RS51488B (el)
SI (2) SI21303A (el)
UA (1) UA89349C2 (el)
WO (1) WO2004035027A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
WO2012014012A1 (es) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
WO2013066280A1 (en) * 2011-10-31 2013-05-10 Mahmut Bilgic Water soluble antipsychotic formulations
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2083622B1 (el) * 1970-03-27 1975-08-22 Sankyo Co
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
HUP9904065A3 (en) * 1996-09-24 2001-10-29 Lilly Co Eli Coated particle formulations containing olanzapine
US6348458B1 (en) * 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
WO2003055438A2 (en) * 2001-12-24 2003-07-10 Sun Pharmaceutical Industries Limited Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
AU2002255196A1 (en) * 2002-04-18 2003-10-27 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions

Also Published As

Publication number Publication date
CA2502582C (en) 2010-08-03
UA89349C2 (uk) 2010-01-25
SI21303A (sl) 2004-04-30
CA2502582A1 (en) 2004-04-29
NO20052408D0 (no) 2005-05-13
US20050288276A1 (en) 2005-12-29
DK1558219T3 (da) 2007-10-29
AU2003269792A1 (en) 2004-05-04
US20110319395A1 (en) 2011-12-29
HRP20050342A2 (hr) 2006-04-30
NO20052408L (no) 2005-07-04
RS51488B (en) 2011-04-30
WO2004035027A1 (en) 2004-04-29
EP1558219A1 (en) 2005-08-03
PL206217B1 (pl) 2010-07-30
PT1558219E (pt) 2008-01-04
DE60316714T2 (de) 2008-07-17
EA008516B1 (ru) 2007-06-29
RS20050292A (en) 2007-08-03
EA200500671A1 (ru) 2005-10-27
SI1558219T1 (sl) 2008-02-29
EP1558219B1 (en) 2007-10-03
HRP20050342B1 (hr) 2013-11-08
ES2295626T3 (es) 2008-04-16
PL376413A1 (en) 2005-12-27
DE60316714D1 (de) 2007-11-15
ATE374600T1 (de) 2007-10-15

Similar Documents

Publication Publication Date Title
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DK1207756T3 (da) Anvendelse af spinosad eller en formulering, der omfatter spinosad
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
RS50360B (sr) Farmaceutske formulacije derivata platine
ATE292453T1 (de) Antivirale arznei
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
WO2005065639A3 (en) Novel pharmaceutical compositions
HUP0500842A2 (hu) Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra
WO2002015933A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
MXPA05013270A (es) Forma de administracion transmucosal con irritacion mucosal reducida. reducida.
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
SE0001916D0 (sv) Novel formulation
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
NO20051261L (no) Morfin-6-glukuronidsalt
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
HRP20050466A2 (en) Pharmaceutical composition comprising a ltb4 antagonists and a cox-2 inhibitor or a combined cox 1/2 inhibitor